Abstract
Chronic lymphocytic thyroiditis, also known as Hashimoto’s thyroiditis, is the most common cause of spontaneously occurring hypothyroidism in adults in the United States. Treatment for this condition is thyroid hormone replacement once hypothyroidism develops since there is no known effective treatment to halt the underlying thyroiditis that eventually destroys the thyroid gland. Selenium supplements have been reported to reduce anti-thyroid antibody titers significantly but not to prevent the eventual development of hypothyroidism. Low-dose naltrexone (LDN) has been promoted in books and on Internet websites as an effective treatment to reduce thyroid inflammation and symptoms in patients with this condition. However, there is no published scientific data to substantiate these claims.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chaker L, Bianco AC, Jonklass J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550–62.
Hu S, Rayman MP. Multiple nutritional factors and the risk of Hashimoto’s thyroiditis. Thyroid. 2017;27(5):597–610.
Wichman J, Winther KH, Bonnema SJ, Hegedus L. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. Thyroid. 2016;26(12):1681–92.
Garber J, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028. And Thyroid 2012 Dec;22(12):1200–35.
Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, American Thyroid Association Task Force on Thyroid Hormone Replacement, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–751.
Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, Hegedüs L. Increased psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide register study. Thyroid. 2014;24(5):802–8.
Quinque EM, Villinger A, Kratzsch J, Karger S. Patient-reported outcomes in adequately treated hypothyroidism – insights from the German versions of ThyQoL, ThySRQ and ThyTSQ. Health Qual Life Outcomes. 2013;11:68.
Samuels MH, Kolobova I, Smeraglio A, Peters D, Janowsky JS, Schuff KG. The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition. J Clin Endocrinol Metab. 2014;99(3):843–51.
Samuels MH, Kolobova I, Smeraglio A, Niederhausen M, Janowsky JS, Schuff KG. Effect of thyroid function variations within the laboratory reference range on health status, mood, and cognition in levothyroxine-treated subjects. Thyroid. 2016;26(9):1173–84.
Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2016;101(4):1318–43.
Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433–512.
Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U, Groenvold M, et al. Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS One. 2016;11(6):e0156925.
Peterson SJ, Cappola AR, Castro MR, et al. Degrees of satisfaction and coexistent diseases in those responding to a survey exploring perceptions about treatment of hypothyroidism. Thyroid. 2018;28(6):707–21.
McAninch EA, Bianco AC. The history and future treatment of hypothyroidism. Ann Intern Med. 2016;164(1):50–6.
Guglielmi R, Frasoldati A, Zini M, Grimaldi F, Gharib H, Garber JR, Papini E. Italian Association of Clinical Endocrinologists Statement-Replacement Therapy for Primary Hypothyroidism: a brief guide for clinical practice. Endocr Pract. 2016;22(11):1319–26.
Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, Hermann M. Hashimoto’ s thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid. 2011;21(2):161–7.
Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123(2):183.e1–9.
Roy A, Laszkowska M, Sundstrom J, Lebwohl B, Green PH, Kämpe O, Ludvigsson JF. Prevalence of celiac disease in patients with autoimmune thyroid disease: a meta-analysis. Thyroid. 2016;26(7):880–90.
Schopick, Julia E and Berkson Burton M. Honest Medicine. 2011.
Smith J. Low dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007;102:820–8.
Parker CE. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;4:CD010410. https://doi.org/10.1002/14651858.CD010410.pub3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
McDermott, M.T. (2019). Low-Dose Naltrexone Treatment of Hashimoto’s Thyroiditis. In: McDermott, M. (eds) Management of Patients with Pseudo-Endocrine Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-22720-3_24
Download citation
DOI: https://doi.org/10.1007/978-3-030-22720-3_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-22719-7
Online ISBN: 978-3-030-22720-3
eBook Packages: MedicineMedicine (R0)